Most authorities recommend starting biological agents upon failure of at least one disease-modifying agent in patients with rheumatoid arthritis. However, owing to the absence of head-to-head studies, there is little guidance about which biological to select. Still, the practicing clinician has to decide. This review explores the application of published evidence to practice, discussing the goals of treatment, the (in) ability to predict individual responses to therapy, and the potential value of indirect comparisons. We suggest that cycling of biological agents, until remission is achieved or until the most effective agent for that individual patient is determined, deserves consideration in the current stage of knowledge.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046505PMC
http://dx.doi.org/10.1186/ar3149DOI Listing

Publication Analysis

Top Keywords

rheumatoid arthritis
8
biological agents
8
applying science
4
science practice
4
practice optimization
4
biological
4
optimization biological
4
biological therapy
4
therapy rheumatoid
4
arthritis authorities
4

Similar Publications

This study aimed to investigate the association between the interleukin-1 beta (IL-1β) gene polymorphism (rs2853550) and the risk of rheumatoid arthritis (RA) in a sample of the Iraqi population. The study included 100 RA patients and 100 healthy controls. Demographic characteristics, including age and gender, were collected and compared between the two groups.

View Article and Find Full Text PDF

Effects of dioscin from Dioscorea nipponica on TL1A/DR3 and Th9 cells in a collagen-induced arthritis mouse model.

Int Immunopharmacol

January 2025

Department of Anatomy, Basic Medical Institute, Chengde Medical University, Chengde 067000 Hebei, China. Electronic address:

Rheumatoid arthritis (RA) is a systemic autoimmune disease, and TL1A and its receptor DR3 play important roles in its pathogenesis. Th9 cells are involved in RA development. Dioscin from Dioscorea nipponica (DDN) has a therapeutic effect on RA, but its effect on TL1A/DR3 and Th9 cells remains unclear.

View Article and Find Full Text PDF

Background: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology. This study aims to explore the potential mechanisms by which solute carrier family 7 member 11 (SLC7A11) influences RA development.

Methods: Collagen-induced arthritis (CIA) mice were constructed to observe disease onset and pathological scores.

View Article and Find Full Text PDF

Poor Prognostic Factors and Unmet Needs in Rheumatoid Arthritis.

Rheumatology (Oxford)

January 2025

Medical University of Vienna, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Spitalgasse 23, Vienna, 1090, Austria.

Prognostic factors in rheumatoid arthritis relate to several aspects, such as prediction of joint damage and loss of function or prediction of response to a particular therapy. Since many decades, it is well established that high disease activity, especially exemplified by swollen joint counts and acute phase reactants, is associated with progression of joint damage. In addition, rheumatoid factor (RF) positive patients, but not patients with anti-citrullinated peptide antibodies (ACPA) are particularly prone to high disease activity and joint destruction.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is an age-related chronic inflammatory disease which may include accelerated biological ageing processes in its pathogenesis. To determine if increased biological age is associated with risk of RA and/or is present once disease is established. We used DNA methylation to compare biological age (epigenetic age) of immune cells in adults at risk of RA and those with confirmed RA, including twins discordant for RA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!